| Clinical Publications |
Scientific Publications |
| December 2022 |
Project Confirm: Accelerated drug approvals for chronic myeloid leukemia
Sweet KL et al. Clin Cancer Res, December 2022
(epub ahead of print) |
|
Management of TKI-resistant chronic phase CML - Review
Hughes TP and Shanmunagathan N. Hematology Am Soc Hematol Educ Program,
December 2022 |
Genetic landscape of chronic myeloid leukemia - Review
Ochi Y. Int J Hematol, December 2022
(epub ahead of print) |
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic-phase: the ASC4FIRST phase III trial
Cortes JE et al. Future Oncol, December 2022
(epub ahead of print)
- open access publication |
Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition
Bütow M et al. Haematologica, December 2022
(epub ahead of print)
– open access publication |
Treatment of CML in pregnancy
Robertson HF and Apperley JF. Hematology Am Soc Hematol Educ Program, December 2022 |
Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
Karg E et al. Front Oncol, December 2022
– open access publication |
Measurable residual disease in leukemia - Review
Branford S and Apperley JF. Haematologica, December 2022
– open access publication |
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukemia (CML) by disrupting glycerophospholipid metabolism
Gonzalez MA et al. Clin Transl Med, December 2022
– open access publication |
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM1 trial
Dulucq S et al. Haematologica, December 2022
– open access publication |
JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?
Tarantini F et al. Hematology, December 2022
|
Chronic myeloid leukemia: the cutting-edge evidence and things we should know
Iriyama N et al. Int J Hematol, December 2022
(epub ahead of print) |
Wee 1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-yH2AX-MDC1
Zeng F et al. Cell Commun Signal, December 2022
– open access publication
|
De novo lymphoid blast phase chronic myeloid leukemia: report and contemporary discussion
Hameed M et al. Hematology, December 2022
– open access publication |
Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicated chronic myeloid leukemia cells
Dudka W et al. BMC Cancer, December 2022
– open access publication
|
Current management of chronic myeloid leukemia myeloid blast crisis - Review
Yohanan B and George B. Clin Med Insights Oncol, December 2022 (epub ahead of print) |
Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells
Zhang J et al. Hematology, December 2022 |
A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia - Review
Ahmed K et al. Front Med (Lausanne), December 2022
– open access publication |
Aberrant DNA methylation status and mRNA expression level of SMG1 gene in chronic myeloid leukemia: A case-control study
Hojjatipour T et al. Cell J, December 2022
|
A review of the therapeutic role of the new third-generation TKI Olverembatinib in chronic myeloid leukemia - Review
Qian H et al. Front Oncol, December 2022
- open access publication |
Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients
Zhang Y et al. Hematology, December 2022
|
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
Ono T et al. Int J Hematol, December 2022
– open access publication |
FUBP3 regulates chronic myeloid leukemia progression through PRC2 complex regulated PAK1-ERK signalling
Sharma M et al. J Cell Mol Med, December 2022
(epub ahead of print)
– open access publication
|
Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
Ureshino H et al. Hematology, December 2022
– open access publication |
Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor
Liu H et al. Eur J Med Chem, December 2022
|
Transplantation in CML in the TKI era: who, when, and how?
Niederwieser C and Kröger N. Hematology Am Soc Hematol Edu Program, December 2022 |
miR-495-3p sensitizes BCR-ABL1 expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance1 gene in T315I mutated cells
Rittavee Y et al. Exp Hematol, December 2022
(epub ahead of print) |
| |
Dvl proteins regulate SMAD1, AHR, mTOR, BRD7 protein expression while differentially regulating canonical and non-canonical Wnt signaling pathways in CML cell lines
Caliskan C et al. Gene, December 2022 (epub ahead of print)
|
| November 2022 |
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Flynn KE et al. Haematologica, November 2022
– open access publication |
BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
Parry N et al. Cell Death Discov, November 2022
– open access publication |
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands
Ector GICG et al. Leuk Lymphoma, November 2022 (epub ahead of print) |
Integrating single-cell transcriptome and network analysis to characterize the therapeutic response of chronic myeloid leukemia
Ma J et al. Int J Mol Sci, November 2022
– open access publication |
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis
Jabbour E et al. Am J Hematol, November 2022 |
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia
Knight A et al. Cancer Immunol Immunother, November 2022 (epub ahead of print) – open access publication |
Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotonib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis - Review
Li S et al. Front Cardiovas Med, November 2022
- open access publication |
Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia
Ma D et al. Oncogene, November 2022
(epub ahead of print) |
Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with chronic myeloid leukemia
Ono T et al. Cancer Sci, November 2022 (epub ahead of print) – open access publication |
Low c-Kit expression identifies primitive therapy-resistant CML stem cells
Shah M et al. JCI Insight, November 2022 (epub ahead of print) – open access publication |
Olverembatinib in chronic myeloid leukemia
Öziskender R et al. Drugs Today (Barc), November 2022
|
Hematopoietic and chronic myeloid leukemia stem cells:
Multi-stability versus lineage restriction - Review
Brown G. Int J Mol Sci, November 2022
– open access publication
|
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation
Xu Z et al. Leuk Lymphoma, November 2022 |
SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
Wu DL eta l. Eur J Med Res, November 2022
– open access publication
|
Extramedullary T-lymphoblastic blast crisis in chronic myeloid leukemia:
A very rare case associated with comutation of ABL1 T315I and H396R
Zhang Y et al. Int J Lab Hematol, November 2022 (epub ahead of print) |
Reciprocal interactions among CobII1, PACSIN2, and SH3BP1 regulate drug resistance in CML
Park K et al. Cancer Med, November 2022
– open access publication
|
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast crisis and was successfully treated with asciminib
Tomassetti S et al. Clin Case Rep, November 2022
– open access publication |
Low c-Kit expression identifies primitive therapy-resistant CML stem cells
Shah M et al. JCI Insight, November 2022
(epub ahead of print)
– open access publication
|
| October 2022 |
Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party in the EBMT
Chalandon Y et al. Am J Hematol, Oct 2022
(epub ahead of print) – open access publication |
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase independent resistance in chronic myeloid leukemia
Barnes EJ et al. Br J Haematol, Oct 2022
(epub ahead of print) |
Dasatinib plus Peg-interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukemia: Results of a multicenter phase 2 study (DASA-Peg IFN Study)
Roy L et al. Br J Haematol, Oct 2022
(epub ahead of print) |
Prognostic impact of ASXL1 mutations in chronic phase CML
Bidikian A et al. Blood Cancer J, Oct 2022
– open access publication |
B-lymphoid blast phase chronic myeloid leukemia: Current Therapeutics
Yohannan B and George B. Int J Mol Sci, Oct 2022 – open access publication |
Non-coding RNAs are implicit in chronic myeloid leukemia therapy-resistance - Review
Rudich A et al. Int J Mol Sci, Oct 2022
– open access publication |
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency
Hochmann MJ et al. Int J Hematol, Oct 2022
(epub ahead of print) |
ACSL1 promotes imatinib-induced chronic myeloid leukemia cell senescene by regulating SIRT1/p53/p21 pathway
Liu W et al. Sci Rep, Oct 2022
– open access publication |
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency
Hochmann MJ et al. Int J Hematol, Oct 2022
(epub ahead of print) |
Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
Su YL et al. Cancer Sci, Oct 2022
– open access publication |
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia - Review
Senapati J et al. Leukemia, Oct 2022
(epub ahead of print) |
IRF4 Gene expression on the trail of molecular response: looking at chronic myeloid leukemia from another perspective
Tarantini F et al. Acta Haematol, Oct 2022
(epub ahead of print) |
Real-world therapeutic response and tyrosine kinase discontinuation in chronic-phase chronic myeloid leukemia: data from the French Observatory
Saugues S et al. Ann Hematol, Oct 2022 |
Histone chaperone ASF1A accelerates chronic myeloid leukemia blast crisis by activating Notch signaling
Yiu X et al. Cell Death Dis, Oct 2022
– open access publication |
Bosutinib-induced late-onset severe liver injury preceded by eopsinophilia
Watanabe N et al. Ann Hematol, Oct 2022 |
|
BCR::ABL1 levels at first month after tyrosine kinase inhibitor discontinuation predict subsequent maintenance of treatment-free remission: A study from the “GRUPPO TRIVENETO LMC”
Di Giusto S et al. Cancer Med, Oct 2022
(epub ahead of print) – open access publication |
|
Volumetric dried blood micro-sampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia
Krützmann ME et a. J Pharm Biomed Anal, Oct 2022 (epub ahead of print)
|
Co-existence of chronic lymphocytic leukemia and chronic myeloid leukemia and underlying pathogenetic mechanisms
Badal S et al. Eur J Haematol, Oct 2022 (epub ahead of print) |
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care
Assanto GM et al. Expert Rev Hematol, Oct 2022 (epub ahead of print)
|
EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells
Vinothkumar K et al. Int J Hematol, Oct 2022
(epub ahead of print) |
CML resistant to 2nd generation TKI’s: Mechanisms, next steps, and new directions
Scalzulli E et al. Curr Hematol Malig Rep, October 2022 (epub ahead of print)
|
Molecular changes in chronic myeloid leukemia during tyrosine kinase inhibitors treatment. Focus on immunological pathways
Janowski M et al. Onco Targets Ther, Oct 2022 – open access publication
|
| |
Association between germline single-nucleotide variants in ADME genes and major molecular response to imatinib in CML patients
Estrada N et al. J Clin Med, Oct 2022
|
| September 2022 |
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
Schönfeld L et al. Leukemia, September 2022
– open access publication |
IFN- α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
Huuhtanen J et al. J Clin Invest, September 2022
– open access publication |
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
Jabbour E and Kantarjian H. Am J Hematol,
September 2022 |
Targeting the PTP1B-BCR-ABL1 interaction for the degradation of T315I mutant BCR-ABL1 in chronic myeloid leukemia
Elgehama A et al. Cancer Sci, September 2022
(epub ahead of print) – open access publication |
CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era
Vaughn JL et al. Bone Marrow Transplant, September 2022 (epub ahead of print) |
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia
Soverini S et al. Leukemia, September 2022 |
Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population
Kockerols CCB et al. Haematologica, September 2022 (epub ahead of print) – open access publication |
Ex vivo expansion of phenotypic and transcriptome CML stem cells
Patel SB et al. Exp Hematol, September 2022
(epub ahead of print) – open access publication |
Deep molecular response in patients with chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TMT614 combined with a tyrosine kinase inhibitor
Takahashi N et al. Cancer Med, September 2022
(epub ahead of print) – open access publication |
Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance
Bührer ED et al. Leukemia, September 2022 (epub ahead of print) – open access publication |
Management of chronic myeloid leukemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicine Agency (AIFA)
Breccia M et al. Br J Haematol, September 2022
– open access publication |
circCRKL, a circ RNA-derived from CRKL, regulates BCR-ABL via sponging miR-877-p5 to promote chronic myeloid leukemia cell proliferation
Wang J et al. J Transl Med, September 2022
– open access publication |
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities – Review
Narli Özdemir Z et al. Int J Hematol, September 2022 (epub ahead of print) |
KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukemia though activating Wnt/ß-catenin pathway
Huang Y et al. Clin Exp Pharmacol Physiol, September 2022
(epub ahead of print)
– open access publication |
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia – Review
Umezawa Y and Sasaki K. Int J Hematol, September 2022 (epub ahead of print) |
|
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitors?
Canon A et al. Leuk Lymphoma, September 2022
(epub ahead of print)
|
|
Asciminib vs bosutinib in CML patients pretreated with ≥ 2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL Study
Yuda J et al. Cancer Med, September 2022
(epub ahead of print) – open access publication
|
|
A unique three-way variant Philadelphia chromosome t(6;9;22) (p21.3;q34;q11.2) in a newly diagnosed patient with chronic myeloid leukemia responded to Flumatinib
Chen L et al. Onco Targets Ther, September 2022
– open access publication |
|
| August 2022 |
Defining higher-risk chronic myeloid leukemia: risk scores, genomic landscape, and prognostication – Review
Shahrin NH et al. Curr Hematol Malig Rep, August 2022 (epub ahead of print) - open access publication |
Reengineering ponatinib to minimize cardiovascular toxicity
Hnatiuk AP et al. Cancer Res, August 2022 |
Onset of blast crisis in chronic myeloid leukemia in treatment-free remission
Dulucq S et al. Haematologica, August 2022
(epub ahead of print) – open access publication |
Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in TKI-resistant CML cells
Kaehler M et al. Oncol Rep, August 2022
– open access publication |
Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia
Johnson-Ansah H et al. Pharmaceutics, August 2022 – open access publication |
Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-alderosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia
Tsuda M et al. Int J Hematol, August 2022
(epub ahead of print) |
Asciminib as a third line option in chronic myeloid leukemia - Review
Laganà A et al. Int J Hematol, August 2022
(epub ahead of print) |
Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors
Hong Y et al. Int Immunopharmacol, August 2022 |
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
Kockerols CCB et al. Haematologica, August 2022 – open access publication |
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR:ABL1-independent resistance to tyrosine kinase inhibitors
Mancini M et al. Front Oncol, August 2022
– open access publication |
Caution in using second generation tyrosine kinase inhibitor, especially for first-line therapy of chronic myeloid leukemia
Gambarcorti-Passerini C et al. Am J Hematol, August 2022 – open access publication |
Identification of key microRNA as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial
Yen R et al. Leukemia, August 2022 (epub ahead of print) |
Real-life analysis and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Luna A et al. Ann Hematol, August 2022
(epub ahead of print) – open access publication |
The mRNA expression of PTEN, LEF1, JAK3, LC3, and p62/SQSTM1 genes in patients with chronic myeloid leukemia
Lak ER et a. Cardiovas Hematol Agents Med Chem, August 2022 |
Olverembatinib (HQP135I), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated CML: results of an open-label, multicenter phase 1/2 trial
Jiang Q et al. J Haematol Oncol, August 2022
– open access publication |
Activin A downregulates the CD69-MT2A axis via p38 MAPK to induce erythroid differentiation that sensitized BCR-ABL-positive cells to imatinib
Chen CW et al. Exp Cell Res, August 2022 |
TKI dosing for chronic phase CML: the case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day)
Tefferi A et al. Am J Hematol, August 2022
(epub ahead of print) |
|
Identification of key microRNA as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial
Yen R et al. Leukemia, August 2022
(epub ahead of print) |
|
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Hehlmann R et al. Leukemia, August 2022
(epub ahead of print) – open access publication |
|
| July 2022 |
Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors
Aslan NA et al. J Oncol Pharma Pract, July 2022
– open access publication |
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Sánchez R et al. Sci Rep, July 2022
– open access publication |
Mechanisms of resistance and implications for treatment strategies in CML - Review
Poudel C et al. Cancers(Basel), July 2022
– open access publication |
Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
Su YJ et al. Cancer Sci, July 2022 (epub ahead of print)
– open access publication |
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase - Review
García-Gutiérrez V et al. J Hematol Oncol, July 2022 – open access publication |
RHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
Zhang H et al. Haematologica, July 2022
(epub ahead of print) – open access publication |
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
Haddad FG et al. Am J Hematol, July 2022 |
Vandetanib drives growth arrest and promotes sensitivity to Imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4
Ma W et al. Mol Oncol, July 2022
– open access publication |
Exposure-efficacy analysis of Asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic-phase
Combes FP et al. Clin Pharmacol Ther, July 2022
(epub ahead of print) |
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia
Peter B et al. Am J Hematol, July 2022
(epub ahead of print)- open access publication |
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor chronic myeloid leukemia patients
Lipton NJ and Lipton JH. Leuk Lymphoma, July 2022 |
Chronic myeloid leukemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype
Harrington P et al. Br J Haematol, July 2022
(epub ahead of print) – open access publication |
Induction-maintenance for the chronic-phase of chronic myeloid leukemia (IMPACT-I): a prospective, single-arm, phase 2 study
Cheung YM et al. Lancet Oncol, July 2022 |
Allosteric enhancement of the BCR-ABL1 kinase inhibition activity of Nilotinib by co-binding of Asciminib
Oruganti B et al. J Biol Chem, July 2022
(epub ahead of print) – open access publication |
Co-variates associated with outcomes of tyrosine kinase inhibitor therapy in persons with chronic myeloid leukemia initially presenting in accelerated phase
Yang S et al. Leukemia, July 2022 |
Complex karyotype with double Philadelphia chromosome and T315l mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient
Davulcu EA et al. Cancer Genet, July 2022
(epub ahead of print) |
Migrating to long-read sequencing for clinical routine BCR-ABL1 TKI resistance mutation screening
Schaal W et al. Cancer Inform, July 2022
– open access publication |
Simultaneous quantification of Dasatinib, Nilotinib, Bosutinib, and Ponatinib using high-performance liquid chromatography-Photodiode array detection
Yokoyama Y et al. J Clin Lab Anal, July 2022
(epub ahead of print) – open access publication |
Treatment of blast phase chronic myeloid leukemia: A rare and challenging entity – Review
Copland M. Br J Haematol, July 2022
(epub ahead of print) – open access publication |
Inability to phosphorylate Y88 of P27Kip1 enforces reduced P27 protein levels and accelerated leukemia progression
Jäkel H et al. Leukemia, July 2022
– open access publication |
Chronic phase CML with sole P190 (e1a2) BCR:ABL1: long-term outcome among ten consecutive cases
Abdelmagid MG et al. Blood Cancer J
– open access publication |
|
| June 2022 |
Asciminib for chronic myeloid leukemia: Next questions - Review
Shanmuganathan N and Hughes TP. Br J Haematol, June 2022 (epub ahead of print) |
CRISPR/Cas9-directied gene trap constitutes a selection system for corrected BCR/ABL leukemic cells in CML
Vuelta E et al. Int J Mol Sci, June 2022
– open access publication |
Initial rate of BCR::ABL1 decline for response prediction in chronic myeloid leukemia
Branford S. Turk J Haematol, June 2022
(epub ahead of print) – open access publication |
Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML
Liu C et al. Cell Metabol, June 2022 |
French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia (In French)
Réa D et al. Bull Cancer, June 2022 (epub ahead of print) |
The dawn of allosteric BCR-ABL1 drugs: from a phenotypic screening hit to an approved drug
Teng M et al. J Med Chem, June 2022
(epub ahead of print) |
Chronic myeloid leukemia: 2022 update on diagnosis, therapy and monitoring
Jabbour E and Kantarjian H. Am J Hematol, June 2022 (epub ahead of print) |
BCR-ABL1∆E7-8-9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Tan Y et al. Hematol Oncol, June 2022
(epub ahead of print) |
Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy
Zhang XS et al. Leukemia, June 2022
(epub ahead of print) |
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
Salmon M et al. Leukemia, June 2022
(epub ahead of print) – open access publication |
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukemia at high risk of cardio toxicity
Di Lisi D et al. ESC Heart Fail, June 2022
– open access publication |
Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission
Yu G et a. Leuk Lymphoma, June 2022
(epub ahead of print) |
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dentritic Neoplasms - Review
Khoury JD et al. Leukemia, June 2022
(epub ahead of print) – open access publication |
Successful preservation of native BCR::ABL1 in chronic myeloid leukemia primary leukocytes reveals a reduced kinase activity
Boni C et al. Front Oncol, June 2022
– open access publication |
Future management of chronic myeloid leukemia: From dose optimization to new agents
Breccia M et al. Curr Cancer Drug Targets
(epub ahead of print)
|
Modified dentritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
Du Z et al. Exp Hematol Oncol, June 2022
– open access publication |
The outcomes of ponatinib therapy in patients with CML resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the Donation Program
Sacha T et al. Clin Lymphoma Myeloma, June 2022
– open access publication |
Atypical activation of signaling downstream of inactivated BCR-ABL mediates chemoresistance in chronic myeloid leukemia
Narasimhan M et al. J Cell Commun Signal, June 2022 (epub ahead of print) – open access publication
|
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia:
a post-marketing surveillance study in Korea
Ahn SY et al. Blood Res, June 2022
(epub ahead of print)
– open access publication
|
Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia
Ozel B et al. Med Oncol, June 2022 |
Out comes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network
Sanz A et al. Blood Cancer J, June 2022
– open access publication
|
|
Bosutinib-induced lung injury: a report of two cases and literature review
Watanabe N et al. Int J Hematol, June 2022
– open access publication |
|
| May 2022 |
How I treat chronic-phase chronic myelogenous leukemia
Berman E. Blood, May 2022 |
Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors
de Almeida FC et al. Front Immunol, April 2022
– open access publication |
Asciminib: new therapeutic option in chronic-phase CML with treatment-failure
Yeung DT et al. Blood, April 2022 (epub ahead of print) |
RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia
Shanmunagathan N et al. J Mol Diagn, May 2022
(epub ahead of print) |
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission
Lu L et al. Br J Haematol, May 2022
(epub ahead of print) – open access publication |
Novel tyrosine kinase inhibitors to target chronic myeloid leukemia
Ciaffaglione V et al. Molecules, May 2022
– open access publication |
Chronic myeloid leukemia: a type of MPN
Samad MA et al. Blood Res, May 2022
(epub ahead of print)
– open access publication |
Chromosomal instability in chronic myeloid leukemia: Mechanistic insights and effects
Senapati J and Sasaki K. Cancers(Basel), May 2022
– open access publication
|
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia – What to look for when treatment-free remission is not an option
Lipton JH et al. Blood Rev, May 2022
(epub ahead of print) – open access publication |
LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients
Shehata AMF et al. Leuk Res, May 2022
|
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Brümmendorf TH et al. Leukemia, May 2022
(epub ahead of print) – open access publication |
Peripheral blood CD26 positive leukemia stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia
Ebjan HF et al. Leuk Res Rep, May 2022
– open access publication
|
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Flynn KE et al. Haematologica, May 2022
(epub ahead of print) – open access publication |
|
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
White HE et al. Leukemia, May 2022
(epub ahead of print) – open access publication |
|
An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia
Yang J et al. Expert Rev Hematol, May 2022
(epub ahead of print) |
|
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM-2 trial
Dulucq S et al. Haematologica, May 2022
(epub ahead of print) – open access publication |
|
Lower tumour burden is associated with better cognitive function in patients with chronic-phase chronic myeloid leukemia
Li Z et al. Leuk Lymphoma, May 2022
(epub ahead of print) |
|
Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience
Szczepanek E et al. Leuk Lymphoma, May 2022
(epub ahead of print) |
|
| April 2022 |
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
Gugliotta G et al. Haematologica, April 2022
(epub ahead of print) – open access publication |
Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide
Zheng X et al. Oncol Lett, April 2022
– open access publication |
Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success
Inzol E et al. Am J Hematol, April 2022
(epub ahead of print) – open access publication |
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
Adnan Awad S et al. Blood Cancer J, April 2022
– open access publication |
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
Haddad F et al. Leuk Lymphoma, April 2022
(epub ahead of print) |
Aberrant hyrdroxymethylation in promoter CpG regions of genes related to the cell cycle apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival
Guru SA et al. BMC Cancer, April 2022
– open access publication |
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation
Shimazu Y et al. Hematol Oncol, April 2022
(epub ahead of print) |
Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy
Li Y et al. Cell Death Discov, April 2022
– open access publication |
Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukemia
Shivarov V and Grigorova D. Br J Haematol, April 2022 (epub ahead of print) – open access publication |
|
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic leukemia in the United Kingdom and The Netherlands
Claudiani S et al. Eur J Haematol, April 2022
(epub ahead of print) |
|
Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?
Bhreathnach Ú and Langabeer SE. Int J Lab, April 2022 (epub ahead of print) – open access publication
|
|
Aleukemic extramedullary blast crisis as an initial presentation of chronic myeloid leukemia with E1A3 BCR-ABL1 fusion transcript
Miyashita N et al. Int Med, April 2022 (epub ahead of print)
– open access publication
|
|
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors
García-Gutiérrez V and Hernandez-Boluda JC. Expert Rev Hematol, May 2022 (epub ahead of print) |
|
| March 2022 |
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
Takahashi N et al. Int J Hematol, March 2022
(epub ahead of print) – open access publication |
Another Philadelphia story
Radich J. Haematologica, March 2022
– open access publication |
Michele Baccarani, August 16, 1942 to December 20, 2021: a gifted life in hematology
Saglio G et al. Bone Marrow Transplant, March 2022 (epub ahead of print) – open access publication |
The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients
Park H et al. Leuk Res, March 2022 |
Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: A feasible option also in real-life: A Campus CML study
Iurlo A et al. Front Oncol, March 2022
– open access publication |
The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia
Kumar R et al. Blood Adv, March 2022
(epub ahead of print) – open access publication |
Prevalence of anemia among chronic myeloid leukemia patients treated with imatinib: A evidence based meta-analysis
Singh AK et al. Curr Rev Clin Exp Pharmacol, March 2022 (epub ahead of print) |
Targeting BCR-ABL in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Roskoski R. Pharmacol Res, March 2022
(epub ahead of print) |
Molecular monitoring of BCR-ABL fusion transcripts in patients with chronic myeloid leukemia during treatment using the endpoint fluorescence method
Amin H and Ahmed S. Lab Med, March 2022 |
A kinase inhibitor which specifically targets the ABL myristate pocket (STAM), but unlike asciminib crosses the blood-brain barrier
Manley PW et al. Bioorg Med Chem Lett, March 2022 |
The clinical significance of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive chronic myeloid leukemia who underwent allogeneic hematopoietic cell transplantation
Tachibana T et al. Transplant Cell Ther, March 2022 (epub ahead of print) |
FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via non-canonical κB-kappa B signaling activation
Yang T et al. J Exp Clin Cancer Res, March 2022
– open access publication |
Outcomes of pregnancies with chronic myeloid leukemia in the tyrosine kinase inhibitor era and literature review
Castillo DL et al. Hematol Rep, March 2022
– open access publication |
Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapyExpression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapy
Toloza MJ et al. Gene, March 2022 |
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentrations in patients with chronic myeloid leukemia receiving first-line nilotinib therapy
Fukuda N et al. Cancer Chemother and Pharmacol, March 2022 (epub ahead of print)
– open access publication |
MiR-199a-3p overexpression suppressed cell proliferation and sensitized chronic myeloid leukemia cells to imatinib by inhibiting mTor signalling
Liu X et al. Acta Hematol, March 2022
(epub ahead of print) |
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukemia
Baccarani M et al. Leukemia, March 2022
(epub ahead of print) – open access publication |
|
Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukemia model
Lindström HJG and Friedmann R. Sci Rep,
March 2022 – open access publication |
|
| February 2022 |
Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation
Shatty D et al. Asia Pac J Clin Oncol, February 2022
– open access publication |
TRIB2 regulates the expression of miR-33a-5p through the ERK/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells
Sun H et al. Int J Oncol, March 2022
(epub ahead of print)
– open access publication
|
Impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A Pairwise and Bayesian Network Meta-Analysis
Chen K et al. Front Oncol, February 2022
– open access publication |
A systematic review of candidate miRNAs, its targeted genes and pathways in CML – An integrated bioinformatical analysis
Elias MH et al. Front Oncol, March 2022
– open access publication |
Extramedullary early T-cell lymphoblastic crisis in a young pregnant chronic myeloid leukemia patient: Diagnosis with fine needle aspiration cytology and flow cytometry
Murugan R et al. Diagn Cytopathol, Feb 2022 (epub ahead of print) |
Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia cells
Ianniciello A and Helgasson GV. Autophagy, March 2022
(epub ahead of print) |
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive phase in Taiwan
Hwang WL et al. Int J Hematol, February 2022 (epub ahead of print) |
Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia
Lee KL et al. Leukemia, March 2022
– open access publication |
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia
Shelton DN et al. PLoS One, March 2022
– open access publication |
Commentary on Dominy et al.: Assessment of qualitative PCR for BCR-ABL1 transcripts in CML: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Branford S. Br J Haematol, February 2022
(epub ahead of print)
– open access publication |
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
Robin JB et al. Ann Hematol, March 2022
(epub ahead of print) |
Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia
Sharma P et al. Int J lab Hematol, February 2022
(epub ahead of print) |
Management of chronic myeloid leukemia and pregnancy:
A Bibliometric Analysis (2000-2020)
Wang Y et al. Front Oncol, March 2022
– open access publication |
Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study)
Sicuranza A et al. Front Oncol, February 2022 – open access publication |
Transcript and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
Kumar V et al. Mol Cell Biochem, February 2022 (epub ahead of print) |
Genomic mechanisms influencing outcome in chronic myeloid leukemia
Fernandes A et al. Cancers(Basel), January 2022 – open access publication |
Olverembatinib: First Approval
Dhillon S et al. Drugs, February 2022
(epub ahead of print) |
Discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a review of the biological factors associated with treatment-free remission
Stuckey R et al. Curr Oncol Rep, February 2022
(epub ahead of print) |
A predictive scoring system for therapy failure in persons with chronic myeloid leukemia receiving initial imatinib therapy
Zhang XS et al. Leukemia, February 2022
(epub ahead of print) |
Validation and refinement of RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia
Lee KL et al. Leukemia, February 2022
(epub ahead of print)
– open access publication |
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
Pokorny R et al. J Oncol Pharm Pract, February 2022
(epub ahead of print)
– open access publication |
Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia
Kamachi K et al. Cancer Lett, February 2022 – open access publication |
| |
Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Closa L et al. HLA, February 2022 |
| |
Waking up CML leukemia stem cells for the kill
Lv K and Tong W. Blood, February 2022
– open access publication |
| |
Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia
Sharma P et al. Int J lab Hematol, February 2022
(epub ahead of print) |
| |
Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study)
Sicuranza A et al. Front Oncol, February 2022 – open access publication |
|
|
Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Closa L et al. HLA, February 2022 |
| January 2022 |
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukemia
Gallipoli P et al. Br J Haematol, January 2022
(epub ahead of print)
– open access publication |
The downregulation of both giant HERCs, HERC1 and HERC2, is an unambiguous feature of chronic myeloid leukemia, and HERC1 levels are associated with leukemia cell differentiation
Shahzad Ali M et al. J Clin Med, January 2022
– open access publication |
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
Januzzi JL et al. J Hematol Oncol, January 2022
– open access publication |
BCR-ABL1 tyrosine kinase complex signalling transduction:
challenges to overcome resistance in chronic myeloid leukemia
Amarante-Mendes GP et al. Pharmaceutics, January 2022
– open access publication |
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors:
Follow-up of patients diagnosed 2002 – 2017 in a complete coverage and nationwide agnostic register study
Dahlén T et al. Am J Hematol, January 2022
(epub ahead of print)
– open access publication |
Imatinib can act as an allosteric activator of ABL kinase
Xie T et al. J Mol Biol, January 2022 |
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
Réa D and Hughes TP. Crit Rev Oncol Hematol,
January 2022
(epub ahead of print)
– open access publication |
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
Tanaka Y et al. Nat Commun, January 2022
– open access publication |
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Dominy KM et al. Br J Haematol, January 2022
(epub ahead of print) |
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis
Louati N et al. J Oncol Pharma Pract, January 2022 |
Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: Who can benefit the most?
Efficace F and Baccarani M. J Natl. Cancer Inst,
January 2022
– open access publication |
Comparative gene expression analysis reveals similarities and differences of chronic myeloid leukemia phases
Schwarz A et al. Cancers(Basel), January 2022
– open access publication |
The progression of chronic myeloid leukemia to myeloid sarcoma: A systematic review
Arzoun H et al. Cureus, January 2022
– open access publication |
P-Loop mutations-negative prognosticators in tyrosine kinase inhibitors resistant chronic myeloid leukemia patients
Kaleem B et al. Int J Lab Hematol, January 2022
(epub ahead of print)
|
Asciminib: First Approval
Deeks ED et al. Drugs, January 2022
(epub ahead of print) |
The prognosis biomarkers based on m6A-related IncRNAs for myeloid leukemia patients
Yang LR et al. Cancer Cell Int, January 2022
– open access publication |
Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors
Shaya J et al. Clin Lymphoma Myeloma Leuk, January 2022
– open access publication |
Pterostilbene downregulated BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
Kawakami S et al. Sci Rep, January 2022
– open access publication |
|
Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Kee KM et al. Leuk Res, January 2022
|
Novel mechanism by a Bis-Pyridinium fullerene derivate to induce apoptosis by enhancing the MEK-ERK pathway in a reactive oxygen species-independent manner in BCR-ABL-positive chronic myeloid leukemia-derived K562 cells
Sumi K et al. Int J Mol, January 2022
– open access publication |
English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
